JP2014521744A5 - - Google Patents

Download PDF

Info

Publication number
JP2014521744A5
JP2014521744A5 JP2014526078A JP2014526078A JP2014521744A5 JP 2014521744 A5 JP2014521744 A5 JP 2014521744A5 JP 2014526078 A JP2014526078 A JP 2014526078A JP 2014526078 A JP2014526078 A JP 2014526078A JP 2014521744 A5 JP2014521744 A5 JP 2014521744A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
cycloalkyl
alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014526078A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014521744A (ja
JP5903162B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/050051 external-priority patent/WO2013025424A1/en
Publication of JP2014521744A publication Critical patent/JP2014521744A/ja
Publication of JP2014521744A5 publication Critical patent/JP2014521744A5/ja
Application granted granted Critical
Publication of JP5903162B2 publication Critical patent/JP5903162B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014526078A 2011-08-17 2012-08-09 糖尿病の治療に有用な新規1,2,3,4−テトラヒドロキノリン誘導体 Expired - Fee Related JP5903162B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161524462P 2011-08-17 2011-08-17
US61/524,462 2011-08-17
PCT/US2012/050051 WO2013025424A1 (en) 2011-08-17 2012-08-09 A Novel 1,2,3,4-Tetrahydroquinoline Derivative Useful for the Treatment of Diabetes

Publications (3)

Publication Number Publication Date
JP2014521744A JP2014521744A (ja) 2014-08-28
JP2014521744A5 true JP2014521744A5 (enExample) 2015-09-24
JP5903162B2 JP5903162B2 (ja) 2016-04-13

Family

ID=46690732

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014526078A Expired - Fee Related JP5903162B2 (ja) 2011-08-17 2012-08-09 糖尿病の治療に有用な新規1,2,3,4−テトラヒドロキノリン誘導体

Country Status (30)

Country Link
US (1) US8431706B2 (enExample)
EP (1) EP2744806B1 (enExample)
JP (1) JP5903162B2 (enExample)
KR (1) KR101570624B1 (enExample)
CN (1) CN103687856B (enExample)
AP (1) AP3589A (enExample)
AR (1) AR087451A1 (enExample)
AU (1) AU2012295372A1 (enExample)
BR (1) BR112014003079A2 (enExample)
CA (1) CA2843474C (enExample)
CL (1) CL2014000357A1 (enExample)
CO (1) CO6880069A2 (enExample)
CR (1) CR20140052A (enExample)
DO (1) DOP2014000018A (enExample)
EA (1) EA022165B1 (enExample)
EC (1) ECSP14013211A (enExample)
ES (1) ES2578165T3 (enExample)
GT (1) GT201400022A (enExample)
IL (1) IL230635A (enExample)
IN (1) IN2014MN00191A (enExample)
MA (1) MA35351B1 (enExample)
MX (1) MX2014001832A (enExample)
PE (1) PE20140831A1 (enExample)
PH (1) PH12014500366A1 (enExample)
SG (1) SG11201401793PA (enExample)
TN (1) TN2014000058A1 (enExample)
TW (1) TWI537262B (enExample)
UA (1) UA110983C2 (enExample)
WO (1) WO2013025424A1 (enExample)
ZA (1) ZA201400705B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014372114A1 (en) 2013-11-14 2016-06-09 Cadila Healthcare Limited Novel heterocyclic compounds
US9957219B2 (en) 2013-12-04 2018-05-01 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
EP3102198B1 (en) 2014-02-06 2020-08-26 Merck Sharp & Dohme Corp. Antidiabetic compounds
CN109666027A (zh) * 2017-10-17 2019-04-23 中国科学院上海药物研究所 一类酰胺结构的gpr40激动剂化合物及其用途
MX2020007283A (es) 2018-01-08 2020-09-10 Celon Pharma Sa Derivados de acido 3-fenil-4-hexinoico como agonistas del receptor acoplado a la proteina g-40.
WO2019160882A1 (en) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2019204609A1 (en) 2018-04-19 2019-10-24 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
BR112020026746A2 (pt) 2018-07-13 2021-03-30 Gilead Sciences, Inc. Composto, composição farmacêutica, métodos para inibir pd-1, pd-l1 e/ou a interação de pd-1/pd-l1 e para tratar câncer, e, kit para tratar ou prevenir câncer ou uma doença ou condição.
CN112955435B (zh) 2018-10-24 2024-09-06 吉利德科学公司 Pd-1/pd-l1抑制剂
CN113906015B (zh) 2019-05-31 2024-03-01 现代药品株式会社 3-(4-(苄氧基)苯基)己-4-炔酸衍生物的新晶型
TWI751585B (zh) * 2019-06-28 2022-01-01 美商美國禮來大藥廠 類升糖素肽1受體促效劑
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ,インク. Gpr119アゴニスト
EP4052790A4 (en) * 2019-10-31 2023-12-27 China Petroleum & Chemical Corporation SUPPORTED CATALYST, ITS PREPARATION METHOD AND ITS APPLICATION
PH12022552277A1 (en) 2020-02-28 2024-03-04 Kallyope Inc Gpr40 agonists
JP2023526625A (ja) 2020-05-19 2023-06-22 キャリーオペ,インク. Ampkアクチベーター
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂
KR102699076B1 (ko) * 2021-04-01 2024-08-27 현대약품 주식회사 3-(4-(벤질옥시)페닐)헥스-4-이노익산 유도체의 신규 용도
CN115317484B (zh) * 2022-08-26 2023-07-18 北京箭牧科技有限公司 Ly2922470在制备预防或治疗脑血管疾病或组织缺血再灌注损伤药物中的应用
CN115671105B (zh) * 2022-11-22 2023-10-27 北京箭牧科技有限公司 Ly2922470在制备预防或治疗肾脏疾病药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
DE60205234T2 (de) * 2001-03-27 2006-05-24 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisochinolin-derivate als urotensin ii rezeptor-antagonisten
EA011010B1 (ru) * 2004-02-27 2008-12-30 Эмджен, Инк. Соединения, модулирующие рецептор gpr40, фармацевтическая композиция, способ лечения заболеваний, чувствительных к модулированию рецептора gpr40 (варианты), способ модулирования функции gpr40 (варианты) и способ модулирования циркулирующей концентрации инсулина
EP1726580A4 (en) * 2004-03-15 2008-02-13 Takeda Pharmaceutical AMINOPHNYLPROPANO ACID DERIVATIVE
EP1731505B1 (en) * 2004-03-30 2015-01-14 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
AR078522A1 (es) * 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
AR078948A1 (es) * 2009-11-30 2011-12-14 Lilly Co Eli Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes

Similar Documents

Publication Publication Date Title
JP2014521744A5 (enExample)
JP2015512931A5 (enExample)
JP2014500861A5 (enExample)
JP2013542218A5 (enExample)
JP2014515013A5 (enExample)
JP2011500550A5 (enExample)
JP2010536766A5 (enExample)
JP2013523733A5 (enExample)
JP2014508811A5 (enExample)
JP2015500843A5 (enExample)
JP2011105738A5 (enExample)
JP2011518833A5 (enExample)
JP2012533546A5 (enExample)
JP2012506896A5 (enExample)
JP2015505296A5 (enExample)
JP2013534248A5 (enExample)
JP2014526533A5 (enExample)
JP2011246469A5 (enExample)
JP2013532130A5 (enExample)
JP2011088926A5 (enExample)
JP2010132677A5 (enExample)
JP2016528273A5 (enExample)
JP2008517020A5 (enExample)
JP2017511368A5 (enExample)
JP2013513607A5 (enExample)